Review



yap1  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Novus Biologicals yap1
    Yap1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 77 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yap1+nb110+58358/YAP1+Antibody+-+BSA+Free/pm41961483-426-9-11
    Average 95 stars, based on 77 article reviews
    yap1 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Western Blot:

    Article Title: Unconventional myosin VI in the heart: Involvement in cardiac dysfunction progressing with age.
    Article Snippet: The following primary antibodies were used: against MVI (25-6791, Proteus, Ramona, CA, USA), Ki67 (in-5698-82) and p-connexin 43 (Ser282) (PA5-64641) (Invitrogen, Waltham, MA, USA), p-PKA (44- 988A) and PKA (PA5-21842) (ThermoFisher Scientific, Waltham, MA, USA), GATA4 (sc-25310) and collagen III (sc-28888) (Santa Cruz Biotechnology, Heidelberg, Germany), p-Akt (#9271), Akt (#9272), pmTOR (#39182), mTOR (#39182), p-S6K (#9234), S6K (#2708), pCREB (#9196), p-Erk 1/2 (#14227), Erk 1/2 (#4695), p-SAPK/JNK (#4668), SAPK/JNK (#9252), p-p38 (#9211), p38 (#9212), HIF-1α (#14179), and α-SMA (#19245) (Cell Signaling Technologies, Danvers, MA, USA), connexin 43 (ab11370), N-cadherin (ab98952), SERCA2 (ab2861), GRP78/BiP (ab21685), vimentin (ab92547), dysferlin (ab124684), dystrophin (ab7164) and VEGFA (ab1316) (Abcam, Cambridge, UK), plakophilin 2 (NBP2-94257) and YAP1 (NB110-58358) (Novus, Centennial, CO, USA), p-connexin 43 (Ser368) (AP0355, ABclonal, Woburn, MA USA), calreticulin (gift from Dr. M. Michalak from the University of Alberta, Edmonton, Canada), and GAPDH (MAB374, Millipore, St. Louis, MO, USA).. The following secondary antibodies were used: HRP-conjugated anti-mouse and anti-rabbit IgG (AP308P and AP307P, respectively; Millipore), anti-rat IgG (ab97057, Abcam).

    Control:

    Article Title: Unconventional myosin VI in the heart: Involvement in cardiac dysfunction progressing with age.
    Article Snippet: The following primary antibodies were used: against MVI (25-6791, Proteus, Ramona, CA, USA), Ki67 (in-5698-82) and p-connexin 43 (Ser282) (PA5-64641) (Invitrogen, Waltham, MA, USA), p-PKA (44- 988A) and PKA (PA5-21842) (ThermoFisher Scientific, Waltham, MA, USA), GATA4 (sc-25310) and collagen III (sc-28888) (Santa Cruz Biotechnology, Heidelberg, Germany), p-Akt (#9271), Akt (#9272), pmTOR (#39182), mTOR (#39182), p-S6K (#9234), S6K (#2708), pCREB (#9196), p-Erk 1/2 (#14227), Erk 1/2 (#4695), p-SAPK/JNK (#4668), SAPK/JNK (#9252), p-p38 (#9211), p38 (#9212), HIF-1α (#14179), and α-SMA (#19245) (Cell Signaling Technologies, Danvers, MA, USA), connexin 43 (ab11370), N-cadherin (ab98952), SERCA2 (ab2861), GRP78/BiP (ab21685), vimentin (ab92547), dysferlin (ab124684), dystrophin (ab7164) and VEGFA (ab1316) (Abcam, Cambridge, UK), plakophilin 2 (NBP2-94257) and YAP1 (NB110-58358) (Novus, Centennial, CO, USA), p-connexin 43 (Ser368) (AP0355, ABclonal, Woburn, MA USA), calreticulin (gift from Dr. M. Michalak from the University of Alberta, Edmonton, Canada), and GAPDH (MAB374, Millipore, St. Louis, MO, USA).. The following secondary antibodies were used: HRP-conjugated anti-mouse and anti-rabbit IgG (AP308P and AP307P, respectively; Millipore), anti-rat IgG (ab97057, Abcam).

    Expressing:

    Article Title: Unconventional myosin VI in the heart: Involvement in cardiac dysfunction progressing with age.
    Article Snippet: The following primary antibodies were used: against MVI (25-6791, Proteus, Ramona, CA, USA), Ki67 (in-5698-82) and p-connexin 43 (Ser282) (PA5-64641) (Invitrogen, Waltham, MA, USA), p-PKA (44- 988A) and PKA (PA5-21842) (ThermoFisher Scientific, Waltham, MA, USA), GATA4 (sc-25310) and collagen III (sc-28888) (Santa Cruz Biotechnology, Heidelberg, Germany), p-Akt (#9271), Akt (#9272), pmTOR (#39182), mTOR (#39182), p-S6K (#9234), S6K (#2708), pCREB (#9196), p-Erk 1/2 (#14227), Erk 1/2 (#4695), p-SAPK/JNK (#4668), SAPK/JNK (#9252), p-p38 (#9211), p38 (#9212), HIF-1α (#14179), and α-SMA (#19245) (Cell Signaling Technologies, Danvers, MA, USA), connexin 43 (ab11370), N-cadherin (ab98952), SERCA2 (ab2861), GRP78/BiP (ab21685), vimentin (ab92547), dysferlin (ab124684), dystrophin (ab7164) and VEGFA (ab1316) (Abcam, Cambridge, UK), plakophilin 2 (NBP2-94257) and YAP1 (NB110-58358) (Novus, Centennial, CO, USA), p-connexin 43 (Ser368) (AP0355, ABclonal, Woburn, MA USA), calreticulin (gift from Dr. M. Michalak from the University of Alberta, Edmonton, Canada), and GAPDH (MAB374, Millipore, St. Louis, MO, USA).. The following secondary antibodies were used: HRP-conjugated anti-mouse and anti-rabbit IgG (AP308P and AP307P, respectively; Millipore), anti-rat IgG (ab97057, Abcam).

    Staining:

    Article Title: Unconventional myosin VI in the heart: Involvement in cardiac dysfunction progressing with age.
    Article Snippet: The following primary antibodies were used: against MVI (25-6791, Proteus, Ramona, CA, USA), Ki67 (in-5698-82) and p-connexin 43 (Ser282) (PA5-64641) (Invitrogen, Waltham, MA, USA), p-PKA (44- 988A) and PKA (PA5-21842) (ThermoFisher Scientific, Waltham, MA, USA), GATA4 (sc-25310) and collagen III (sc-28888) (Santa Cruz Biotechnology, Heidelberg, Germany), p-Akt (#9271), Akt (#9272), pmTOR (#39182), mTOR (#39182), p-S6K (#9234), S6K (#2708), pCREB (#9196), p-Erk 1/2 (#14227), Erk 1/2 (#4695), p-SAPK/JNK (#4668), SAPK/JNK (#9252), p-p38 (#9211), p38 (#9212), HIF-1α (#14179), and α-SMA (#19245) (Cell Signaling Technologies, Danvers, MA, USA), connexin 43 (ab11370), N-cadherin (ab98952), SERCA2 (ab2861), GRP78/BiP (ab21685), vimentin (ab92547), dysferlin (ab124684), dystrophin (ab7164) and VEGFA (ab1316) (Abcam, Cambridge, UK), plakophilin 2 (NBP2-94257) and YAP1 (NB110-58358) (Novus, Centennial, CO, USA), p-connexin 43 (Ser368) (AP0355, ABclonal, Woburn, MA USA), calreticulin (gift from Dr. M. Michalak from the University of Alberta, Edmonton, Canada), and GAPDH (MAB374, Millipore, St. Louis, MO, USA).. The following secondary antibodies were used: HRP-conjugated anti-mouse and anti-rabbit IgG (AP308P and AP307P, respectively; Millipore), anti-rat IgG (ab97057, Abcam).

    Labeling:

    Article Title: Unconventional myosin VI in the heart: Involvement in cardiac dysfunction progressing with age.
    Article Snippet: The following primary antibodies were used: against MVI (25-6791, Proteus, Ramona, CA, USA), Ki67 (in-5698-82) and p-connexin 43 (Ser282) (PA5-64641) (Invitrogen, Waltham, MA, USA), p-PKA (44- 988A) and PKA (PA5-21842) (ThermoFisher Scientific, Waltham, MA, USA), GATA4 (sc-25310) and collagen III (sc-28888) (Santa Cruz Biotechnology, Heidelberg, Germany), p-Akt (#9271), Akt (#9272), pmTOR (#39182), mTOR (#39182), p-S6K (#9234), S6K (#2708), pCREB (#9196), p-Erk 1/2 (#14227), Erk 1/2 (#4695), p-SAPK/JNK (#4668), SAPK/JNK (#9252), p-p38 (#9211), p38 (#9212), HIF-1α (#14179), and α-SMA (#19245) (Cell Signaling Technologies, Danvers, MA, USA), connexin 43 (ab11370), N-cadherin (ab98952), SERCA2 (ab2861), GRP78/BiP (ab21685), vimentin (ab92547), dysferlin (ab124684), dystrophin (ab7164) and VEGFA (ab1316) (Abcam, Cambridge, UK), plakophilin 2 (NBP2-94257) and YAP1 (NB110-58358) (Novus, Centennial, CO, USA), p-connexin 43 (Ser368) (AP0355, ABclonal, Woburn, MA USA), calreticulin (gift from Dr. M. Michalak from the University of Alberta, Edmonton, Canada), and GAPDH (MAB374, Millipore, St. Louis, MO, USA).. The following secondary antibodies were used: HRP-conjugated anti-mouse and anti-rabbit IgG (AP308P and AP307P, respectively; Millipore), anti-rat IgG (ab97057, Abcam).



    Similar Products

    yap1  (Novus Biologicals)
    95
    Novus Biologicals yap1
    Yap1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yap1+nb110+58358/YAP1+Antibody+-+BSA+Free/pm41961483-426-9-11
    Average 95 stars, based on 1 article reviews
    yap1 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    rabbit anti yap1  (Novus Biologicals)
    95
    Novus Biologicals rabbit anti yap1
    Rabbit Anti Yap1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yap1+nb110+58358/YAP1+Antibody+-+BSA+Free/pm41932885-363-159-162
    Average 95 stars, based on 1 article reviews
    rabbit anti yap1 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    e cadherin  (Novus Biologicals)
    95
    Novus Biologicals e cadherin
    (A) Schematic of the experimental design using the MDCK cell jamming model. Subconfluent cells progressively undergo crowding, during which cell velocity, <t>E-cadherin</t> and YAP levels, and RNA expression were quantified across 15 time points. (B) Root-mean-square cell velocity ( v rms ) measured from the same time series exhibits an earlier decline (≈70 h) than the E-cadherin and YAP transitions. (C) E-cadherin immunofluorescence showing the progressive maturation of adherens junctions during crowding. Scale bar = 50 µ m. (D) YAP immunofluorescence demonstrating the gradual enrichment of YAP in the cytoplasm. (E) Quantification of the junction-to-cytoplasm E-cadherin intensity ratio reveals a time-dependent increase following a sigmoidal trend (LogEC 50 ≈ 90 h). Scale bar = 50 µ m. (F) Quantification of the cytoplasmic-to-nuclear YAP intensity ratio shows a sigmoidal increase (LogEC 50 ≈ 90 h), indicating reduced nuclear YAP localization. (G) Principal component analysis of bulk RNA-seq profiles depicts a nonlinear transcriptional trajectory with an inflection near 70 h. (H) Gene set enrichment analysis identifies pathways associated with epithelial differentiation, signaling, and metabolism that significantly change over time. (I–K) Expression dynamics of key metabolic gene sets, glycolysis, OXPHOS, and fatty-acid metabolism, show coordinated downregulation beginning near 70 h, preceding adherens junction maturation and YAP relocalization.
    E Cadherin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yap1+nb110+58358/YAP1+Antibody+-+BSA+Free/bio_rxiv__64898__2026__02__09__704880-169-16-20
    Average 95 stars, based on 1 article reviews
    e cadherin - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti yap1  (Novus Biologicals)
    95
    Novus Biologicals anti yap1
    (A) Schematic of the experimental design using the MDCK cell jamming model. Subconfluent cells progressively undergo crowding, during which cell velocity, <t>E-cadherin</t> and YAP levels, and RNA expression were quantified across 15 time points. (B) Root-mean-square cell velocity ( v rms ) measured from the same time series exhibits an earlier decline (≈70 h) than the E-cadherin and YAP transitions. (C) E-cadherin immunofluorescence showing the progressive maturation of adherens junctions during crowding. Scale bar = 50 µ m. (D) YAP immunofluorescence demonstrating the gradual enrichment of YAP in the cytoplasm. (E) Quantification of the junction-to-cytoplasm E-cadherin intensity ratio reveals a time-dependent increase following a sigmoidal trend (LogEC 50 ≈ 90 h). Scale bar = 50 µ m. (F) Quantification of the cytoplasmic-to-nuclear YAP intensity ratio shows a sigmoidal increase (LogEC 50 ≈ 90 h), indicating reduced nuclear YAP localization. (G) Principal component analysis of bulk RNA-seq profiles depicts a nonlinear transcriptional trajectory with an inflection near 70 h. (H) Gene set enrichment analysis identifies pathways associated with epithelial differentiation, signaling, and metabolism that significantly change over time. (I–K) Expression dynamics of key metabolic gene sets, glycolysis, OXPHOS, and fatty-acid metabolism, show coordinated downregulation beginning near 70 h, preceding adherens junction maturation and YAP relocalization.
    Anti Yap1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yap1+nb110+58358/YAP1+Antibody+-+BSA+Free/pmc13055844-74-63-65
    Average 95 stars, based on 1 article reviews
    anti yap1 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic of the experimental design using the MDCK cell jamming model. Subconfluent cells progressively undergo crowding, during which cell velocity, E-cadherin and YAP levels, and RNA expression were quantified across 15 time points. (B) Root-mean-square cell velocity ( v rms ) measured from the same time series exhibits an earlier decline (≈70 h) than the E-cadherin and YAP transitions. (C) E-cadherin immunofluorescence showing the progressive maturation of adherens junctions during crowding. Scale bar = 50 µ m. (D) YAP immunofluorescence demonstrating the gradual enrichment of YAP in the cytoplasm. (E) Quantification of the junction-to-cytoplasm E-cadherin intensity ratio reveals a time-dependent increase following a sigmoidal trend (LogEC 50 ≈ 90 h). Scale bar = 50 µ m. (F) Quantification of the cytoplasmic-to-nuclear YAP intensity ratio shows a sigmoidal increase (LogEC 50 ≈ 90 h), indicating reduced nuclear YAP localization. (G) Principal component analysis of bulk RNA-seq profiles depicts a nonlinear transcriptional trajectory with an inflection near 70 h. (H) Gene set enrichment analysis identifies pathways associated with epithelial differentiation, signaling, and metabolism that significantly change over time. (I–K) Expression dynamics of key metabolic gene sets, glycolysis, OXPHOS, and fatty-acid metabolism, show coordinated downregulation beginning near 70 h, preceding adherens junction maturation and YAP relocalization.

    Journal: bioRxiv

    Article Title: Cell jamming transition is regulated by mitochondrial pyruvate transport and endocytosis

    doi: 10.64898/2026.02.09.704880

    Figure Lengend Snippet: (A) Schematic of the experimental design using the MDCK cell jamming model. Subconfluent cells progressively undergo crowding, during which cell velocity, E-cadherin and YAP levels, and RNA expression were quantified across 15 time points. (B) Root-mean-square cell velocity ( v rms ) measured from the same time series exhibits an earlier decline (≈70 h) than the E-cadherin and YAP transitions. (C) E-cadherin immunofluorescence showing the progressive maturation of adherens junctions during crowding. Scale bar = 50 µ m. (D) YAP immunofluorescence demonstrating the gradual enrichment of YAP in the cytoplasm. (E) Quantification of the junction-to-cytoplasm E-cadherin intensity ratio reveals a time-dependent increase following a sigmoidal trend (LogEC 50 ≈ 90 h). Scale bar = 50 µ m. (F) Quantification of the cytoplasmic-to-nuclear YAP intensity ratio shows a sigmoidal increase (LogEC 50 ≈ 90 h), indicating reduced nuclear YAP localization. (G) Principal component analysis of bulk RNA-seq profiles depicts a nonlinear transcriptional trajectory with an inflection near 70 h. (H) Gene set enrichment analysis identifies pathways associated with epithelial differentiation, signaling, and metabolism that significantly change over time. (I–K) Expression dynamics of key metabolic gene sets, glycolysis, OXPHOS, and fatty-acid metabolism, show coordinated downregulation beginning near 70 h, preceding adherens junction maturation and YAP relocalization.

    Article Snippet: Following three washes with PBS, cells were incubated for 30 minutes with the following primary antibodies: E-cadherin (Abcam, ab11512), YAP (Novus Biologicals, NB110-58358), RhoA (Cell Signaling Technology, 2117T), Rac-1 GTP (NewEast Biosciences, 26903), or EEA1 (BD Biosciences, 610456).After washing three times with PBS, cells were incubated for 30 minutes at room temperature with secondary antibodies—anti-mouse Alexa Fluor 488 or anti-rabbit Alexa Fluor 647 (Invitrogen, A21042 and 4414S, respectively)—together with DAPI (Abcam, ab228549) and either phalloidin (Invitrogen, A12379) or actin stain (Invitrogen, R37110).

    Techniques: RNA Expression, Immunofluorescence, RNA Sequencing, Expressing